Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Infection of mucosal epithelium by papillomaviruses is responsible for the induction of genital and oral warts and plays a critical role in the development of human cervical and oropharyngeal cancer. We have employed a canine model to develop a systemic vaccine that completely protects against experimentally induced oral mucosal papillomas. The major capsid protein, L1, of canine oral papillomavirus (COPV) was expressed in Sf9 insect cells in native conformation. L1 protein, which self-assembled into virus-like particles, was purified on CsCl gradients and injected intradermally into the foot pad of beagles. Vaccinated animals developed circulating antibodies against COPV and became completely resistant to experimental challenge with COPV. Successful immunization was strictly dependent upon native L1 protein conformation and L1 type. Partial protection was achieved with as little as 0.125 ng of L1 protein, and adjuvants appeared useful for prolonging the host immune response. Serum immunoglobulins passively transferred from COPV L1-immunized beagles to naive beagles conferred protection from experimental infection with COPV. Our results indicate the feasibility of developing a human vaccine to prevent mucosal papillomas, which can progress to malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Schiffman, M. H., Bauer, H. M., Hoover, R. N., Glass, A. G., Cadell, D. M., Rush, B. B., Scott, D. R., Sherman, M. E., Kurman, R. J., Wacholder, S., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.958 · Cited by 1,210
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,110
Identification of a transformation-specific antigen induced by an avian sarcoma virus
BRUGGE, J. S., & ERIKSON, R. L. (1977) · Nature · doi:10.1038/269346a0 · Cited by 888
zur Hausen, H. (1991) · Science · doi:10.1126/science.1659743 · Cited by 784
LORINCZ, A. T., REID, R., JENSON, B. A., GREENBERG, M. D., LANCASTER, W., & KURMAN, R. J. (1992) · Obstetrics & Gynecology · doi:10.1097/00006250-199203000-00002 · Cited by 775
EPIDEMIOLOGY OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION
KOUTSKY, L. A., GALLOWAY, D. A., & HOLMES, K. K. (1988) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036020 · Cited by 711
Heterogeneity of the human papillomavirus group
de Villiers, E. M. (1989) · Journal of Virology · doi:10.1128/jvi.63.11.4898-4903.1989 · Cited by 665
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
Kirnbauer, R., Taub, J. W., Greenstone, H. L., Roden, R. B. S., Dürst, M., Gissmann, L., Lowy, D. R., & Schiller, J. T. (1993) · Journal of Virology · doi:10.1128/jvi.67.12.6929-6936.1993 · Cited by 608
Breitburd, F., Kirnbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., Schiller, J. T., & Lowy, D. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3959-3963.1995 · Cited by 589
Rose, R. C., Bonnez, W., Reichman, R. C., & Garcea, R. L. (1993) · Journal of Virology · doi:10.1128/jvi.67.4.1936-1944.1993 · Cited by 381
Genital human papillomavirus infection.
Lowy, D. R., Kirnbauer, R., & Schiller, J. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2436 · Cited by 214
Christensen, N. D., Höpfl, R. M., DiAngelo, S. L., Cladel, N. M., Patrick, S. D., Welsh, P. A., Budgeon, L. R., Reed, C. A., & Kreider, J. W. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-9-2271 · Cited by 152
Synthesis and assembly of infectious bovine papillomavirus particles in vitro
Zhou, J., Stenzel, D. J., Sun, X.-Y., & Frazer, I. H. (1993) · Journal of General Virology · doi:10.1099/0022-1317-74-4-763 · Cited by 120
Lim, P., Jenson, A. B., Cowsert, L. M., Nakai, Y., Lim, L. Y., Jin, X. W., & Sundberg, J. P. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/162.6.1263 · Cited by 83
Self-citationFractionation of Shope papilloma virus in cesium chloride density gradients
Breedis, C., Berwick, L., & Anderson, T. F. (1962) · Virology · doi:10.1016/0042-6822(62)90084-3 · Cited by 68
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Papillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
“However, in animal models of vaccination, passive antibody is sufficient for protection (18, 50, 171, 177), and the high level of vaccine efficacy against infection in humans suggests that antibody is the effector mechanism (51, 123).”
BackgroundA Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Virus-like particles in vaccine development
Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.115 · Cited by 845
Metadata
- Authors
- Suzich, J. A., Ghim, S. J., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., Newsome, J. A., Jenson, A. B., & Schlegel, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-12-05
- Volume
- 92
- Issue
- 25
- Pages
- 11553-11557
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2049095033
- Cited by
- 668
- References
- 16
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.